DEFM14A: Exact Sciences to be Acquired by Abbott for $105/Share Cash

Exact Sciences Corporation will be acquired by Abbott Laboratories for $105.00 per share in cash, representing a significant premium to recent trading prices.

Summary

• Exact Sciences Corporation (Exact) will merge with and into Badger Merger Sub I, Inc., a wholly-owned subsidiary of Abbott Laboratories (Abbott), with Exact continuing as the surviving corporation and a direct, wholly-owned subsidiary of Abbott.
• Each outstanding share of Exact common stock will be converted into the right to receive $105.00 in cash, without interest and subject to tax withholding.
• The Per Share Merger Consideration of $105.00 represents a premium of approximately 51% over Exact's closing share price on November 18, 2025, and a 77% premium over the volume-weighted average trading price for the 60 consecutive trading days ended November 18, 2025.
• Exact's Board of Directors unanimously determined the merger is advisable and in the best interests of Exact and its stockholders, recommending a vote FOR the Merger Agreement Proposal, the Compensation Proposal, and the Adjournment Proposal.
• The merger is subject to stockholder approval, regulatory clearances (including HSR Act), and other customary closing conditions.
• The transaction is expected to close before the end of the second calendar quarter of 2026.
• Upon completion, Exact common stock will be delisted from Nasdaq and deregistered from the SEC.

Sentiment

Score: 8

Explanation: The sentiment is highly positive for Exact Sciences shareholders due to the substantial cash premium offered (51% over unaffected price, 77% over 60-day VWAP) and the certainty of an all-cash transaction. The unanimous board recommendation and fairness opinion further support this positive outlook for shareholders, despite the loss of independence and potential future growth.

Positives

• Shareholders will receive a fixed cash amount of $105.00 per share, providing certainty of value and immediate liquidity.
• The Per Share Merger Consideration represents a substantial premium of 51% over the unaffected closing share price on November 18, 2025, and 77% over the 60-day volume-weighted average price.
• The all-cash consideration eliminates long-term business and execution risks associated with Exact operating as a standalone public company.
• Exact's Board of Directors unanimously recommended the merger, supported by a fairness opinion from Centerview Partners LLC.
• The merger is not subject to any financing condition, as Abbott has committed financing of up to $20 billion.

Negatives

• Existing shareholders will forgo the opportunity to realize potential long-term value from Exact's successful execution of its current strategy as an independent company.
• The exchange of Exact common stock for cash will be a taxable transaction for U.S. federal income tax purposes.
• Exact engaged in negotiations only with Abbott, and the non-solicitation covenant restricts Exact's ability to seek other potential buyers after signing the agreement.
• A termination fee of $628,694,446 is payable by Exact to Abbott under specified circumstances, which could deter competing acquisition proposals.

Risks

• The merger might not be consummated in a timely manner, or at all, if closing conditions are not satisfied or waived, including necessary regulatory approvals.
• Regulatory authorities (FTC, DOJ, state attorneys general, non-U.S. jurisdictions) could challenge the merger, seek divestiture of substantial assets, or impose burdensome conditions.
• Potential litigation and/or regulatory actions related to the merger or Exact's business could prevent or delay completion and incur significant costs.
• The announcement and pendency of the merger could distract Exact's management and disrupt business operations, potentially affecting financial results.
• Restrictions in the Merger Agreement on Exact's conduct of business prior to completion could delay or prevent the pursuit of certain business opportunities.
• Some Exact executive officers and directors have interests in the merger that differ from, or are in addition to, those of general stockholders, creating potential conflicts of interest.

Future Outlook

The merger is expected to close before the end of the second calendar quarter of 2026, subject to stockholder approval and regulatory clearances. Following the merger, Exact Sciences Corporation will become a direct, wholly-owned subsidiary of Abbott Laboratories, and its common stock will be delisted from Nasdaq and deregistered from the SEC. Exact will no longer file periodic or other reports with the SEC. The long-term value of Exact as an independent company will not be realized by current shareholders.

Management Comments

• Kevin Conroy, Chairman, President, and CEO of Exact, confirmed his willingness to continue involvement with Exact or Abbott in a consulting or other capacity following the closing of the proposed transaction, if requested by Mr. Ford.
• Exact's Board of Directors unanimously determined that the Merger Agreement, the Merger, and other contemplated transactions are advisable and in the best interests of Exact and its stockholders.

Industry Context

Exact Sciences is a leading provider of cancer screening and diagnostics tests, including well-established brands like Cologuard and Oncotype DX, and innovative solutions such as Cancerguard and Oncodetect. Abbott Laboratories is a global healthcare leader with a diverse portfolio spanning diagnostics, medical devices, nutritionals, and branded generic medicines. This acquisition represents a strategic move by Abbott to significantly expand its presence and capabilities in the high-growth cancer diagnostics market, integrating Exact's innovative product line into its broader healthcare technology offerings. The consolidation reflects a trend in the healthcare industry towards larger players acquiring specialized diagnostic companies to enhance their market position and product portfolios.

Comparison to Industry Standards

• Centerview Partners LLC's discounted cash flow analysis of Exact resulted in an implied equity value per share range of $78.70 to $136.35, compared to the Per Share Merger Consideration of $105.00.
• Centerview's selected public company analysis, using EV/2026E Revenue Trading Multiples, yielded an implied per share equity value range of $77.45 to $104.45, based on a reference range of 4.5x to 6.0x (median of selected companies was 5.4x).
• Centerview's selected precedent transactions analysis, using EV/NTM Revenue Multiples, resulted in an implied per share equity value range of $75.75 to $110.05, based on a reference range of 4.5x to 6.5x.
• Centerview's precedent premia paid analysis, based on transactions since 2010, indicated a premium range of 30.0% to 45.0% over the target company's unaffected stock price. The $105.00 Per Share Merger Consideration represents a 51% premium over Exact's closing price on November 18, 2025, which is above this historical range, suggesting a favorable offer.

Management Changes

Corporate Governance

Legal Proceedings

• Stockholder litigation related to the Merger Agreement or the transactions contemplated thereby may be filed in the future. Exact will promptly advise Abbott of any such proceedings and give Abbott the opportunity to participate in the defense and settlement discussions.

Related Party Transactions

• Executive officers and directors of Exact have interests in the merger that are different from, or in addition to, the interests of general stockholders, including treatment of equity awards, potential severance benefits, and make-whole payments related to Section 280G of the Internal Revenue Code. These interests were considered by the Board in its evaluation and negotiation of the Merger Agreement.

Stakeholder Impact

• Shareholders: Will receive $105.00 cash per share, realizing a significant premium and immediate liquidity, but will no longer participate in Exact's future growth as an independent entity.
• Employees: Continuing employees will receive no less favorable base salary, target annual cash incentive, and severance benefits for one year post-merger. Target long-term incentive opportunities will be no less favorable than those provided to similarly situated Abbott employees. Certain equity awards will be assumed by Abbott, and others will cash out.
• Customers and Suppliers: The announcement and pendency of the merger could potentially affect relationships with customers and suppliers, though the company is obligated to preserve these relationships.
• Management: Executive officers and directors have specific compensation and indemnification arrangements tied to the merger, which were considered by the Board.
• Regulatory Bodies: The merger requires various regulatory approvals, including antitrust clearances, which will involve scrutiny from governmental authorities.

Next Steps

• Exact stockholders will vote on the Merger Agreement Proposal, Compensation Proposal, and Adjournment Proposal at a Special Meeting on February 20, 2026.
• The parties will continue efforts to obtain all necessary regulatory approvals and clearances, including under the HSR Act and other competition laws.
• Upon satisfaction or waiver of all closing conditions, the merger will be consummated, expected before the end of the second calendar quarter of 2026.
• Exact common stock will be delisted from Nasdaq and deregistered under the Exchange Act after the merger closes.

Key Dates

Recommendation

For existing shareholders, the unanimous recommendation by the Board of Directors, coupled with a fairness opinion from Centerview Partners LLC, strongly suggests accepting the $105.00 per share cash offer. The significant premium (51% over unaffected price, 77% over 60-day VWAP) provides immediate and certain value, de-risking future standalone operational and market uncertainties. For investors considering an arbitrage play, if the stock trades below $105.00 and the likelihood of deal completion remains high, it presents a 'strong buy' opportunity to capture the spread, given the all-cash nature and committed financing.

Keywords

Merger, Acquisition, Exact Sciences, Abbott Laboratories, Cash Consideration, Healthcare Diagnostics, Cancer Screening, Corporate Governance, SEC Filing, Stockholder Vote, Regulatory Approval, Delisting, Deregistration